Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient

Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a phase III trial when compared to physician's c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cold Spring Harb Mol Case Stud
Main Authors: Colombo, Ilaria, Garg, Swati, Danesh, Arnavaz, Bruce, Jeffrey, Shaw, Patricia, Tan, Qian, Quevedo, Rene, Braunstein, Marsela, Oza, Amit M., Pugh, Trevor, Lheureux, Stephanie
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory Press 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6913142/
https://ncbi.nlm.nih.gov/pubmed/31836588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/mcs.a004341
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados